Matinas Biopharma Holdings Inc. Revenue 2014–2023
Matinas Biopharma Holdings Inc. annual/quarterly revenue history and growth rate from 2014 to 2023. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Matinas Biopharma Holdings Inc. revenue for the quarter ending March 31, 2023 was 1.1 M, a 3188.03% increase year-over-year.
- Matinas Biopharma Holdings Inc. revenue for the twelve months ending March 31, 2023 was 3.3 M, a 965.94% increase year-over-year.
- Matinas Biopharma Holdings Inc. annual revenue for 2023 was 1.1 M, a 65.62% decrease from 2022.
- Matinas Biopharma Holdings Inc. annual revenue for 2022 was 3.2 M, a 9560.61% increase from 2021.
- Matinas Biopharma Holdings Inc. annual revenue for 2021 was 33000, a 79.16% decrease from 2020.
- Matinas Biopharma Holdings Inc. annual revenue for 2020 was 158333.
Matinas Biopharma Holdings Inc. (MTNB) — Frequently Asked Questions
Matinas Biopharma Holdings Inc. (MTNB) is a publicly traded US company. It has a market capitalization of $3M. In fiscal 2023 it reported revenue of $1M and net income of -$23M. Explore MTNB's stock price, financial statements, earnings history, margins and key ratios below.
What is Matinas Biopharma Holdings Inc.'s market cap?
Matinas Biopharma Holdings Inc. (MTNB) has a market capitalization of $3M.
What is the MTNB stock price?
MTNB trades at $0.80 (-0.25% on the day).
How much revenue does Matinas Biopharma Holdings Inc. make?
Matinas Biopharma Holdings Inc. reported revenue of $1M in fiscal 2023.
Is MTNB profitable?
In fiscal 2023, Matinas Biopharma Holdings Inc. reported net income of -$23M.